Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China · Delayed Price · Currency is CNY 8.88
+0.17 (1.95%)
Nov 6, 2026, 3:00 PM CST
SHA:603707 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,335 | 14,589 | 21,439 | 24,169 | 29,075 | 52,058 | |
Market Cap Growth | -11.72% | -31.95% | -11.29% | -16.87% | -44.15% | 59.17% |
Enterprise Value | 13,451 | 14,311 | 21,794 | 25,024 | 30,396 | 54,143 |
Last Close Price | 8.88 | 8.92 | 12.99 | 14.56 | 17.36 | 30.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 33.99 | 25.09 | 25.95 | - | 26.65 | 49.14 |
Forward PE | 19.30 | 14.80 | 17.95 | 19.44 | 19.56 | 38.80 |
PS Ratio | 3.52 | 3.66 | 5.46 | 6.15 | 7.83 | 14.12 |
PB Ratio | 2.07 | 2.12 | 3.30 | 4.17 | 4.72 | 9.64 |
P/TBV Ratio | 2.22 | 2.29 | 3.56 | 4.39 | 4.91 | 10.13 |
P/FCF Ratio | 14.68 | 23.43 | 21.56 | 20.14 | 231.92 | 214.34 |
P/OCF Ratio | 9.94 | 12.34 | 14.28 | 14.93 | 48.83 | 76.15 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.30 | 3.59 | 5.56 | 6.37 | 8.19 | 14.69 |
EV/EBITDA Ratio | 15.19 | 14.95 | 19.15 | - | 26.18 | 40.86 |
EV/EBIT Ratio | 22.62 | 19.92 | 22.63 | - | 29.76 | 43.96 |
EV/FCF Ratio | 13.78 | 22.98 | 21.92 | 20.85 | 242.46 | 222.93 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.37 | 0.34 | 0.32 | 0.45 | 0.48 | 0.38 |
Debt / EBITDA Ratio | 2.89 | 2.45 | 1.83 | - | 2.56 | 1.55 |
Debt / FCF Ratio | 2.62 | 3.78 | 2.09 | 2.17 | 23.70 | 8.45 |
Net Debt / Equity Ratio | -0.13 | -0.05 | 0 | 0.12 | 0.26 | 0.21 |
Net Debt / EBITDA Ratio | -1.00 | -0.37 | 0.00 | -3.96 | 1.36 | 0.86 |
Net Debt / FCF Ratio | -0.90 | -0.57 | 0.00 | 0.59 | 12.61 | 4.67 |
Asset Turnover | - | 0.40 | 0.41 | 0.40 | 0.41 | 0.46 |
Inventory Turnover | - | 0.65 | 0.54 | 0.67 | 0.34 | 0.34 |
Quick Ratio | - | 1.30 | 1.59 | 0.94 | 0.96 | 0.88 |
Current Ratio | - | 2.35 | 3.41 | 2.35 | 3.07 | 3.06 |
Return on Equity (ROE) | 6.21% | 8.69% | 13.45% | -3.17% | 18.78% | 23.26% |
Return on Assets (ROA) | - | 4.52% | 6.33% | -2.13% | 7.00% | 9.66% |
Return on Invested Capital (ROIC) | 7.84% | 9.17% | 12.35% | -4.66% | 13.11% | 17.84% |
Return on Capital Employed (ROCE) | - | 10.10% | 12.90% | -5.20% | 14.00% | 20.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.94% | 3.99% | 3.85% | -0.78% | 3.75% | 2.04% |
FCF Yield | 6.81% | 4.27% | 4.64% | 4.96% | 0.43% | 0.47% |
Dividend Yield | 1.13% | 1.11% | 0.75% | 0.61% | 0.65% | 0.34% |
Payout Ratio | 58.33% | 37.56% | 25.81% | - | 20.78% | 18.10% |
Buyback Yield / Dilution | -0.63% | 2.23% | -4.66% | 3.03% | -2.98% | 0.43% |
Total Shareholder Return | 0.50% | 3.34% | -3.91% | 3.64% | -2.32% | 0.77% |